Jefferies analysts expect a regulatory filing for rocatinlimab later this year, with a product launch in 2026.

Amgen and Kyowa Kirin announced preliminary top-line results from the ASCEND study, evaluating the investigational therapy ...

On September 9, Seema Shah, Chief Global Strategist at Principal Asset Management, appeared on CNBC for an interview to ...

Suddenly one obesity asset has come to define Amgen but executives see a fuller portfolio that will bring the big biotech ...

Thousand Oaks, California Wednesday, September 10, 2025, 10:00 Hrs [IST] ...

Amgen Inc. (NASDAQ:AMGN) and Kyowa Kirin released preliminary topline results from the ASCEND study evaluating rocatinlimab ...

Results from the Phase III ASCEND trial (NCT05882877) showed rocatinlimab maintained long-term efficacy with a favorable ...

Amgen and Kyowa Kirin have announced initial top-line findings from the Phase III ASCEND trial assessing the investigational ...

Amgen (AMGN) stock in focus as the company and Kyowa Kirin (KYKOF) report Phase 3 data showing their atopic dermatitis drug, ...

Amgen (AMGN) and Kyowa Kirin announced preliminary top-line results from the ASCEND study evaluating rocatinlimab, an ...

Across the Phase 3 ROCKET program including ASCEND, the incidence of gastrointestinal ulceration events with rocatinlimab to date is less than 1 per 100 patient-years. The ASCEND study is ongoing and ...

Investing.com -- Sanofi (EPA:SASY) shares fell more than 9% on Thursday after the drugmaker reported results from a large trial of its experimental eczema treatment amlitelimab that showed weaker ...